摘要
目的:评价米安色林与多虑平治疗抑郁症的临床疗效和安全性。方法:将53例符合CCMD-3抑郁症诊断标准的抑郁症患者随机分为两组,分别给予米安色林和多虑平治疗,于治疗前和治疗后1、2、4、6周末分别采用汉密顿抑郁量表、临床疗效总体评定量表及不良反应量表评定。结果:米安色林与多虑平总体疗效相似,两组比较差异无显著性(P>0.05)。米安色林组治疗第一周就起效,两组治疗前与治疗后比较HAMD量表差异均有显著性(P<0.01),两组间比较差异无显著性(P>0.05),米安色林组的不良反应少于多虑平组。结论:米安色林是一种安全有效的新一代抗抑郁药物,适合老年病人使用。
Objective：To investigate the clinical effect and safety of mianserin and doxepin in the treatment of depression. Methods： 55 patients with depressive disorder corresponding to the CCMD-3 were randomly divided into two groups,which were treated with mianserin （mlanserin group） or doxepin （doxepin group）. Hamilton rating scale of depression （HAMD）, clinical global impression （CGI） and treatment emergent symptom scale （TESS） were used to evaluate the changes of clinical symptoms and side effects at baseline and 1,2,4 and 6 weeks after treatment respectively. Results：There were no significant differences in CGI and HAMD score between two group （P〉 0.05）. The adverse reaction in miansefin group was less than that in doxepin group （P〈0.01）. Conclusion：The results suggested that the mianserin was a new,safe and effective anti-depressant,and suited for use in senile patients with this disease.
出处
《现代医药卫生》
2006年第6期817-818,共2页
Journal of Modern Medicine & Health
